Michels Family Financial LLC Acquires New Holdings in Novartis AG (NYSE:NVS)

Michels Family Financial LLC bought a new position in shares of Novartis AG (NYSE:NVS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,482 shares of the company’s stock, valued at approximately $339,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Human Investing LLC purchased a new position in shares of Novartis during the 4th quarter worth approximately $25,000. Raiffeisen Bank International AG acquired a new stake in Novartis during the 4th quarter valued at $25,000. Union Bancaire Privee UBP SA purchased a new position in Novartis during the fourth quarter worth $27,000. Bellwether Advisors LLC acquired a new position in shares of Novartis in the fourth quarter worth $38,000. Finally, Fourth Dimension Wealth LLC purchased a new stake in shares of Novartis in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. UBS Group reissued a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. Barclays reissued an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. BNP Paribas upgraded Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Finally, Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Novartis currently has an average rating of “Hold” and an average target price of $123.38.

Novartis Stock Performance

Shares of NYSE:NVS opened at $112.77 on Friday. The business has a 50-day moving average of $109.87 and a two-hundred day moving average of $105.85. The firm has a market capitalization of $238.21 billion, a PE ratio of 19.18, a P/E/G ratio of 1.70 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. Novartis AG has a 12 month low of $96.06 and a 12 month high of $120.92.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.16. Novartis had a net margin of 23.56% and a return on equity of 37.24%. The firm had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. As a group, research analysts forecast that Novartis AG will post 8.45 earnings per share for the current year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.